Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy.

Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, Sinclair DA. · 2010

Read Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. by Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, Sinclair DA. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3034180.txt.

Introduction

Hafner and coauthors linked in 2010 a longevity related enzyme to protection against age related heart thickening. As hearts age, a pore inside their energy producing mitochondria opens too often, weakening the cells. The enzyme, called SIRT3 in short, removes chemical tags from other proteins. The team found it strips one such tag from the pore's regulator protein.

Mice lacking the enzyme showed more pore opening and swollen mitochondria in heart cells as they aged. By just over a year old, their hearts were thickened and scarred, and they fared worse under added heart stress. A drug that blocks the pore regulator rescued the cell defect. The work points to the tag removal step as a guard against heart aging, and as a possible drug target.

Catalog record

CREATORHafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, Sinclair DA.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3034180

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy By Angela V Hafner, Jing Dai, Ana P Gomes, Chun-Yang Xiao, Carlos M Palmeira, Anthony Rosenzweig, David A Sinclair Published in: Aging (Albany NY) DOI: 10.18632/aging.100252 ABSTRACT Abstract Cardiac failure is a leading cause of age-related death, though its root cause remains unknown. Mounting evidence implicates a decline in mitochondrial function due to increased opening of the mitochondrial permeability transition pore (mPTP). Here we report that the NAD+-dependent deacetylase SIRT3 deacetylates the regulatory component of the mPTP, cyclophilin D (CypD) on lysine 166, adjacent to the binding site of cyclosporine A, a CypD inhibitor. Cardiac myocytes from mice lacking SIRT3 exhibit an age-dependent increase in mitochondrial swelling due to increased mPTP opening, a phenotype that is rescued by cyclosporine A. SIRT3 knockout mice show accelerated signs of aging in the heart including cardiac hypertrophy and fibrosis at 13 months of age. SIRT3 knockout mice are also hypersensitive to heart stress induced by transverse aortic constriction (TAC), as evidenced by cardiac hypertrophy, fibrosis, and increased mortality. Together, these data show for the first time that SIRT3 activity is necessary to prevent mitochondrial dysfunction and cardiac hypertrophy during aging and shed light on new pharmacological approaches to delaying aging and treating diseases in cardiac muscle and possibly other post-mitotic tissues. Keywords: sirtuin, SIRT3, mitochondria, acetylated Cyclophilin D, cyclosporine A, acetylation, cardiac, heart, mitochondrial permeability transition, mPTP INTRODUCTION The “Mitochondrial Theory of Aging” posits that a decline in mitochondrial function over time is an underlying cause of aging [1, 2]. There are many observations consistent with this theory, including that mitochondria of young animals are relatively small and bioenergetically efficient but over time they become less numerous, swollen, and chronically depolarized [3]. Increasing evidence implicates a multi-protein complex called the mitochondrial permeability transition pore (mPTP) in the decline in mitochondrial dysfunction with age. Within young cells, mitochondria are impermeable to most ions and solutes, allowing them to maintain membrane potential and store Ca2+[4]. As age advances, however, small disturbances to cellular homeostasis increasingly trigger mPTP formation. Well known triggers include increased levels of ROS and increased Ca2+[5]. Acute triggering of the mPTP can lead to apoptosis whereas low-level, chronic triggering results in mitochondrial swelling, membrane de-polarization, and the destruction of defective mitochondria by autophagy [6]. After three decades of research, the mechanisms that underlie increased mitochondrial membrane permeability with age remains poorly understood. The structure of the mPTP includes the voltage-dependent ion channel (VDAC), adenine nucleotide translocator (ANT), and cyclophilin D (CypD). Binding of CypD to ANT initiates a tunnel-like structure that connects the mitochondrial matrix with the cytosol [7]. The therapeutic value of maintaining the mPTP in a closed state is highlighted by the resistance of CypD knockout mice (Ppif−/−) to a variety of diseases, including autoimmune encephalomyelitis (EAE), sarcoglycan deficiency, laminin deficiency, collagen VI deficiency, ALS (SODG93A), cardiac ischemia-reperfusion injury, and Alzheimer's disease (AD) [8, 9]. These findings have made CypD a drug target of high interest [10, 11]. Unfortunately, pharmacological inhibitors of CypD, such as cyclosporine A (CsA), also inhibit the structurally-related cyclophilins CypA and CypB, which are critical for immune function [12]. Thus, understanding how the mPTP is regulated could identify ways to specifically inhibit the mPTP without compromising immunity. The mammalian sirtuins are a family of seven protein deacetylases that are increasingly thought to underlie many of the health benefits of calorie restriction [13]. What makes sirtuins distinct from other deacetylases is their requirement for NAD+ as a co-substrate [14]. There are three mitochondrial sirtuins, SIRT3, SIRT4 and SIRT5, which are known to regulate fatty acid oxidation, respiration, amino acid metabolism, and the urea cycle [15, 16]. Known substrate targets include acetyl coenzyme A synthetase 2 (ACS2) [17, 18], glutamate dehydrogenase (GDH) [19], and long-chain acyl coenzyme A dehydrogenase (LCAD) [20]. SIRT3 can also act as a tumor suppressor by lowering levels of ROS and possibly by altering cellular metabolism [21]. We recently reported that cell survival in response to genotoxic stress is governed by the levels of mitochondrial NAD+ (mNAD+) [22], not on the levels of cytoplasmic NAD+, as previously thought. Using cell culture, we also identified the mitochondrial sirtuin SIRT3 as a downstream mediator of this cell survival pathway. In this study, we explore the physiological relevance of this process in a major post-mitotic tissue, the heart, and identify the acetylation of lysine 166 on CypD as a critical target of SIRT3 that dictates the pace of aging and age-related diseases in cardiac tissue. RESULTS SIRT3 delays opening of the mPTP in aged cardiac muscle Based on our previous work, we hypothesized that SIRT3 might increase cell survival by regulating a mitochondrial protein that dictates cell viability. We focused on the heart, a post-mitotic tissue where mitochondria are critical for sustained function, making it an ideal organ system for evaluating mitochondrial function and cell survival during aging and cell stress. To assess the role of SIRT3 in mitochondrial function and cell survival in the heart, mitochondria were isolated from hearts of both wild-type and SIRT3−/− mice at various ages and tested for alterations in the susceptibility of mitochondria to opening of the mPTP, a well-known characteristic of aged tissues [23]. We utilized the Ca2+-overload swelling assay, a sensitive assay for mPTP opening. At 3 and 6 months of age, there was no difference between the wild-type and SIRT3−/− samples (Figure 1A, B) but by 16 months of age, the mitochondria isolated from the hearts of the SIRT3−/− mice were significantly more prone to Ca2+-induced mitochondrial swelling (Figure 1C). This sensitivity was completely rescued by the mPTP inhibitor CsA, demonstrating that the defect in the aged SIRT3−/− tissues was likely caused by increased mPTP opening. Thus, SIRT3 suppresses the increase in mPTP formation in the heart during aging. [Figure: SIRT3 prevents mitochondrial permeability transition in cardiac tissue during aging.Mitochondrial swelling induced by Ca2+. Mitochondria from 3 (A), 6 (B) and 16 months old (C) wt and SIRT3−/− mouse hearts subjected to Ca2+-induced mitochondrial swelling, measured as % decrease in the initial optical density (OD540) in the presence or absence of 1 μM CsA (n=4 per group and age). All error bars show s.e.m.] CypD is acetylated on K166 To identify potential interactors that might provide clues as to how SIRT3 prevents mPTP opening during aging, we performed immunoprecipitation experiments with SIRT3 and subjected the precipitated material for identification by mass spectrometry. The predominant interactors with SIRT3 were two components of the mPTP, namely ANT and VDAC. Extensive analysis of these proteins, however, failed to identify an acetylated lysine that was a direct target of SIRT3 (data not shown). Although we did not detect CypD as an interactor in these immunoprecipitation experiments, our observation that CsA reversed the SIRT3−/− mitochondrial phenotype (see Figure 1C), strongly indicated that CypD was directly involved. To test this possibility, we first immunoprecipitated CypD and identified lysine 166 (K166) as a site of acetylation (Figure 2A, B). Interestingly this site is highly conserved from yeast to human (Figure 2C). During the course of this study, acetylation of K166 was also described [24] but incorrectly reported as K145 because the authors did not include the mitochondrial targeting sequence.

Read the complete text